Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.

da Silva GN, de Camargo EA, Salvadori DM.

Mol Biol Rep. 2012 Dec;39(12):10373-82. doi: 10.1007/s11033-012-1916-1. Epub 2012 Oct 9.

PMID:
23053941
2.

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.

da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos Júnior GA, Sakamoto-Hojo ET, Salvadori DM.

Exp Biol Med (Maywood). 2010 Jul;235(7):814-24. doi: 10.1258/ebm.2010.009322.

PMID:
20558835
3.

MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.

da Silva GN, de Camargo EA, Sávio AL, Salvadori DM.

Mol Biol Rep. 2014 Jul;41(7):4613-21. doi: 10.1007/s11033-014-3332-1. Epub 2014 Mar 21.

PMID:
24652204
4.

Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells.

da Silva GN, Evangelista AF, Magalhães DA, Macedo C, Búfalo MC, Sakamoto-Hojo ET, Passos GA, Salvadori DM.

Mol Biol Rep. 2011 Aug;38(6):4159-70. doi: 10.1007/s11033-010-0536-x. Epub 2010 Nov 30.

PMID:
21116856
5.
6.

Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.

Nordentoft I, Dyrskjøt L, Bødker JS, Wild PJ, Hartmann A, Bertz S, Lehmann J, Orntoft TF, Birkenkamp-Demtroder K.

BMC Cancer. 2011 Apr 14;11:135. doi: 10.1186/1471-2407-11-135.

7.

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.

Liu Y, Kwiatkowski DJ.

Mol Cancer Ther. 2015 Jan;14(1):174-82. doi: 10.1158/1535-7163.MCT-14-0622-T. Epub 2014 Oct 27.

8.

Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance.

Hernández-Vargas H, Rodríguez-Pinilla SM, Julián-Tendero M, Sánchez-Rovira P, Cuevas C, Antón A, Ríos MJ, Palacios J, Moreno-Bueno G.

Breast Cancer Res Treat. 2007 Apr;102(2):157-72. Epub 2006 Oct 13.

PMID:
17039268
9.

Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer.

Gazzaniga P, Silvestri I, Gradilone A, Scarpa S, Morrone S, Gandini O, Gianni W, Frati L, Aglianò AM.

Anticancer Drugs. 2007 Feb;18(2):179-85.

PMID:
17159604
10.
11.

Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.

Salem SD, Abou-Tarboush FM, Saeed NM, Al-Qadasi WD, Farah MA, Al-Buhairi M, Al-Harbi N, Alhazza I, Alsbeih G.

Gene. 2012 May 1;498(2):300-7. doi: 10.1016/j.gene.2012.01.099. Epub 2012 Feb 14.

PMID:
22353361
12.

Cell cycle kinetics, apoptosis rates, DNA damage and TP53 gene expression in bladder cancer cells treated with allyl isothiocyanate (mustard essential oil).

Savio AL, da Silva GN, de Camargo EA, Salvadori DM.

Mutat Res. 2014 Apr;762:40-6. doi: 10.1016/j.mrfmmm.2014.02.006. Epub 2014 Mar 10.

PMID:
24625788
13.

Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.

Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Gaivão I, Cardoso ML, Colaço A, Santos L, Oliveira P.

J Toxicol Environ Health A. 2012;75(13-15):788-99. doi: 10.1080/15287394.2012.690325.

PMID:
22788366
14.

Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.

Papadopoulos EI, Yousef GM, Scorilas A.

Tumour Biol. 2015 May;36(5):3197-207. doi: 10.1007/s13277-014-2190-8. Epub 2015 Apr 2.

PMID:
25833690
15.

Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.

Fechner G, Perabo FG, Schmidt DH, Haase L, Ludwig E, Schueller H, Blatter J, Mller SC, Albers P.

Urology. 2003 Feb;61(2):468-73.

PMID:
12597983
16.

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.

Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, Verweij F, De Cobelli O, Pece S, Del Tacca M, Danesi R.

Br J Cancer. 2006 Aug 7;95(3):289-97. Epub 2006 Jul 25.

17.
18.

[Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].

Wang H, Liu Z, Wang ZP, Li FY, Zhao Y, Chen GP, Li DC.

Zhonghua Zhong Liu Za Zhi. 2013 Jun;35(6):412-7. Chinese.

PMID:
24119899
19.

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

Denlinger CE, Rundall BK, Keller MD, Jones DR.

Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14.

PMID:
15464472
20.

Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53.

Pauwels B, Korst AE, Andriessen V, Baay MF, Pattyn GG, Lambrechts HA, Pooter CM, Lardon F, Vermorken JB.

Radiat Res. 2005 Nov;164(5):642-50.

PMID:
16238441
Items per page

Supplemental Content

Write to the Help Desk